Accelerate Drug Discovery and Development

Accelerate Drug Discovery and Development

Industry-approved fluidic-free standard for label-free molecular interaction analysis


Written bySartorius
| 1 min read
Register for free to listen to this article
Listen with Speechify
0:00
1:00

Most assays with fluorescent or radioactive labels are endpoint assays, meaning the data is relevant to only one point in time—usually the end of the assay. Such assays mask the complexity of a binding interaction providing limited drug candidate characteristics, target binding or analyte concentration and quality. Analytical techniques that measure protein quantity and quality are used in nearly all stages of research, process development, and manufacturing of biotherapeutics. Despite their many limitations, ELISA assays have been used for decades for affinity measurements and protein quantitation in physiological and process samples.

Download the resource to learn how Octet® BLI Instruments overcome analytical challenges, courtesy of Sartorius.

Add Lab Manager as a preferred source on Google

Add Lab Manager as a preferred Google source to see more of our trusted coverage.

Related Topics

Loading Next Article...
Loading Next Article...

CURRENT ISSUE - January/February 2026

How to Build Trust Into Every Lab Result

Applying the Six Cs Helps Labs Deliver Results Stakeholders Can Rely On

Lab Manager January/February 2026 Cover Image